Hydrocortisone Valerate

Introduction Overview

Generic Name

hydrocortisone valerate

Brand Name

Westcort

Dosage Form

ointment

Drug Class

topical steroids

Pharmacokinetics

Absorption:
Hydrocortisone valerate, the active ingredient in Westcort, is a topical corticosteroid designed for dermatologic use. When applied to the skin, the extent of its percutaneous absorption is influenced by multiple factors including the formulation vehicle, skin condition, and integrity of the epidermal barrier. Absorption is generally adequate to elicit local anti-inflammatory effects without significant systemic exposure under normal use. However, increased absorption may occur in conditions where the skin barrier is compromised, inflamed, or when occlusive dressings are applied. Studies indicate that occlusive dressings can dramatically enhance penetration when maintained for prolonged periods, such as 96 hours, while shorter occlusion (up to 24 hours) does not substantially increase absorption. Such enhanced absorption may elevate the risk of systemic side effects.

Distribution:
Following dermal absorption, hydrocortisone valerate is distributed locally in the skin layers, targeting cellular receptors to exert its anti-inflammatory effects. Minimal systemic distribution occurs with proper use; however, systemic bioavailability can increase if absorption is enhanced by occlusion, compromised skin, or large application areas. The compound is lipophilic, allowing it to penetrate epidermal and dermal layers effectively. Once absorbed systemically, it binds to corticosteroid receptors and plasma proteins such as albumin. Distribution to other tissues beyond the site of application remains limited under standard use, mitigating systemic corticosteroid-related adverse effects.

Metabolism:
Metabolism of hydrocortisone valerate primarily occurs locally within the skin as well as systemically if absorbed. In the skin, esterases hydrolyze hydrocortisone valerate to hydrocortisone, the active corticosteroid moiety, which then binds glucocorticoid receptors on keratinocytes, fibroblasts, and immune cells. Systemically absorbed drug undergoes hepatic metabolism via reduction and conjugation pathways, consistent with the metabolism of endogenous corticosteroids. Cytochrome P450 enzymes, particularly CYP3A4, facilitate hepatic metabolism. The rapid biotransformation reduces systemic exposure and risk of prolonged systemic corticosteroid effects. There is limited formation of inactive metabolites that are subsequently excreted.

Elimination:
Elimination of systemically absorbed hydrocortisone valerate and its metabolites occurs primarily through renal excretion. Metabolites, mainly conjugated corticosteroids, are excreted in urine with minimal fecal elimination. The half-life of hydrocortisone and its esters after systemic absorption is relatively short, usually around 1.5 to 3 hours, leading to little accumulation with normal topical dosing. The topical route limits systemic accumulation, and excretion kinetics largely parallel those of endogenous corticosteroids. In cases of excessive absorption or overdose, elimination parameters remain consistent but systemic corticosteroid effects may be more evident.

Dosage Forms

Available Dosage Forms:
Westcort is supplied exclusively as a topical ointment formulation containing 0.2% hydrocortisone valerate. The ointment base is hydrophilic and consists of carbomer 934, mineral oil, propylene glycol, sodium lauryl sulfate, sorbic acid, steareth-2, steareth-100, stearyl alcohol, water, and white petrolatum to optimize percutaneous absorption and moisturization.

Dosages for Adults and Adolescents:
The recommended dosage for adult patients is to apply Westcort ointment as a thin film to the affected skin area two to three times daily, depending on the severity and extent of the dermatosis. Treatment should continue until control of symptoms is achieved and then be discontinued to minimize potential adverse effects. If no improvement occurs within two weeks, reevaluation of diagnosis and treatment approach is necessary.

Specific Patient Populations:
Pediatric patients have not been extensively studied with Westcort ointment; thus, safety and efficacy data are insufficient. Due to higher body surface area to weight ratios in children, they are at an increased risk of hypothalamic-pituitary-adrenal (HPA) axis suppression and corticosteroid-related systemic side effects. Use in pediatric populations should be cautious and under close medical supervision.

Packaging and Strength Details:
Westcort ointment is available in tubes containing 15 g, 45 g, and 60 g of ointment, each containing 2 mg of hydrocortisone valerate per gram (0.2% concentration). This provides flexibility in dispensing quantities appropriate to the severity and extent of dermatologic conditions.

Mechanism Of Action

Hydrocortisone valerate, the active component of Westcort, exerts its therapeutic effects primarily through glucocorticoid receptor activation in skin cells. Upon topical application, hydrocortisone valerate penetrates the epidermis and is hydrolyzed to the active corticosteroid hydrocortisone. Hydrocortisone binds to intracellular glucocorticoid receptors, resulting in a receptor-ligand complex that translocates to the nucleus and modulates gene transcription.

This transcriptional modulation leads to upregulation of anti-inflammatory proteins, such as lipocortins, which inhibit phospholipase A2 activity. This inhibition prevents the release of arachidonic acid from membrane phospholipids, thereby reducing the downstream synthesis of pro-inflammatory mediators including prostaglandins and leukotrienes. The suppression of these mediators decreases inflammation, vasodilation, edema, and leukocyte infiltration, producing the characteristic anti-inflammatory and antipruritic effects.

Additionally, hydrocortisone valerate induces vasoconstriction in dermal blood vessels, contributing to decreased redness and swelling at the site of application. The combined anti-inflammatory, vasoconstrictive, and immunosuppressive actions reduce local dermatitis and pruritus symptoms in corticosteroid-sensitive dermatoses.

Compared to other topical corticosteroids, hydrocortisone valerate is classified as a medium potency agent, offering effective control of inflammation with a favorable safety profile when used appropriately. Clinical studies confirm its efficacy in relieving symptoms of eczema, psoriasis, and other corticosteroid-responsive dermatoses. The pharmacologic actions align well with the class effects observed for synthetic corticosteroids and are consistent with extensive clinical usage and data supporting topical corticosteroid therapies.

Pharmacological Actions

Anti-inflammatory action through inhibition of phospholipase A2 and reduction of arachidonic acid metabolites
Antipruritic effect resulting from decreased release of inflammatory mediators
Vasoconstrictive properties leading to reduced dermal blood flow and erythema
Immunosuppressive activity that modulates immune cell function within skin tissue
Suppression of leukocyte infiltration and edema formation in inflamed skin areas
Inhibition of fibroblast proliferation and collagen synthesis with chronic use
Reduction in cytokine and chemokine production involved in inflammatory responses
Stabilization of lysosomal membranes preventing release of proteolytic enzymes
Decreased capillary permeability contributing to diminished swelling and redness
Modulation of gene transcription regulating inflammatory and anti-inflammatory proteins

Therapeutic Or Clinical Uses

Relief of inflammatory manifestations of corticosteroid-responsive dermatoses in adults
Treatment of pruritus associated with various dermatological conditions
Management of eczema and atopic dermatitis with moderate inflammation
Control of psoriasis plaques and lesions with medium potency corticosteroid therapy
Reduction of allergic contact dermatitis symptoms
Treatment of seborrheic dermatitis affecting non-facial areas
Alleviation of skin inflammation due to insect bites or mild skin irritation
Supportive therapy in adult patients with lichen planus and other inflammatory dermatoses
Use as topical anti-inflammatory in dermatological conditions unresponsive to mild potency corticosteroids
Temporary relief of symptoms associated with dermatoses where corticosteroid therapy is indicated

Side Or Adverse Effects

Worsening of existing skin condition in approximately 2% of patients
Transient itching or burning sensation at application site
Localized irritation and redness following topical application
Development of eczema, particularly in pediatric patients
Pruritus and stinging reported in a subset of treated individuals
Dryness and scaling of skin after prolonged use
Possible skin atrophy characterized by thinning of epidermis and dermis
Formation of striae (stretch marks) with chronic or improper use
Hypopigmentation or lightening of treated skin areas
Perioral dermatitis and acneiform eruptions in some cases
Folliculitis and secondary skin infections due to local immunosuppression
Allergic contact dermatitis leading to delayed healing or worsening
Miliaria (sweat retention rash) associated with occlusive application
Systemic symptoms such as reversible hypothalamic-pituitary-adrenal (HPA) axis suppression under extensive or occlusive use
Rare reports of Cushing’s syndrome and hyperglycemia secondary to systemic absorption

Precautions

Avoid use on broken, infected, or ulcerated skin unless under physician supervision
Monitor patients for signs of HPA axis suppression with extensive or occlusive application
Discontinue use if irritation or allergic reaction develops
Avoid application to face, groin, or underarms unless specifically directed due to sensitivity of these areas
Not recommended for use in diaper areas because diapers may act as occlusive dressings enhancing absorption
Use with caution in pediatric patients due to increased systemic absorption risk
Evaluate adrenal function with ACTH stimulation or cortisol testing when used extensively
Instruct patients not to cover treated skin with occlusive dressings unless directed
Caution in pregnant women; assess risk-benefit ratio due to potential teratogenicity
Careful use in nursing mothers; unknown if topical use results in significant milk levels
Avoid prolonged or excessive dosing to minimize local and systemic adverse effects
In cases of secondary skin infections, use appropriate antimicrobial therapy
Advise patients to report any signs of local or systemic adverse effects promptly
Use the minimal effective potency and duration to reduce risk of adverse reactions
Regularly reassess clinical necessity of continued corticosteroid therapy

Warnings

Potential for reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with extensive or prolonged use
Risk of glucocorticosteroid insufficiency upon withdrawal after significant systemic absorption
Possible development of Cushing’s syndrome, hyperglycemia, and glucosuria with systemic exposure
Increased systemic toxicity risk in pediatric patients due to larger skin surface area-to-body mass ratio
Avoid occlusive dressings during therapy unless specifically directed by physician
Discontinue therapy if secondary skin infection develops and initiate appropriate antimicrobial treatment
Not recommended for use with other topical steroids to avoid additive adverse effects
Cautious use in pregnancy; teratogenic effects noted in animal studies at high doses
Use with care in the elderly and patients with underlying adrenal insufficiency
Monitor patients for signs of local adverse reactions such as skin atrophy and telangiectasia
Do not use on eyes or mucous membranes to prevent severe local irritation
Promptly discontinue if allergic contact dermatitis is suspected
Avoid long-term continuous therapy to prevent skin thinning and striae formation
Careful monitoring for signs of increased intra-cranial pressure in pediatric patients
Consider alternative treatments if no improvement occurs within two weeks

Contraindication

Known hypersensitivity to hydrocortisone valerate or any component of the ointment base
Localized or systemic infections of the skin caused by bacteria, fungi, or viruses unless specific anti-infective therapy is administered
Use in patients with untreated skin tuberculosis or other skin infections contraindicated
Avoid use in rosacea and perioral dermatitis due to potential exacerbation
Contraindicated in patients with viral skin infections such as herpes simplex, varicella, or vaccinia
Not to be used in the presence of cutaneous fungal infections without concurrent antifungal treatment
Use contraindicated for ophthalmic conditions or near eye areas
Known allergy or sensitivity to topical corticosteroids or any inactive ingredients
Contraindicated when there is a history of corticosteroid-induced hypersensitivity reactions
Avoid use on ulcerative or open wounds
Not for systemic corticosteroid replacement therapy
Should not be used in patients with perianal or genital pruritus without diagnosis

Drug Interactions

Concurrent use with other topical corticosteroids may increase risk of HPA axis suppression and local adverse effects
Use with systemic corticosteroids can potentiate systemic side effects and toxicity
Combination with immunosuppressive drugs may increase risk of infections
Concurrent use with dermatologic agents that irritate the skin (e.g., salicylic acid, retinoids) may increase irritation
May alter skin response to allergens and interfere with diagnostic skin tests
Use with ketoconazole and other strong CYP3A4 inhibitors can potentially elevate corticosteroid levels systemically if absorbed
Concurrent use with anticoagulants may enhance bleeding risk due to corticosteroid-induced vessel fragility
Use with vaccines should be cautiously considered due to possible immunosuppression
Topical application might reduce efficacy of live vaccines administered locally
Avoid simultaneous use with topical or systemic drugs known to impair skin barrier function that may increase absorption
Combination with agents causing photosensitivity may increase risk of skin damage
Use with systemic agents metabolized by CYP3A4 may require monitoring for altered corticosteroid effects
No significant documented interactions with common dermatologic antifungals or antibacterials under supervised use
Topical drug interactions are generally localized; systemic interactions uncommon but possible with extensive use
Patients should inform healthcare providers of all concomitant medications to assess potential interactions

Preparations Of The Drug

Westcort® ointment containing 0.2% hydrocortisone valerate as active ingredient
Hydrophilic ointment base composed of carbomer 934, dried sodium phosphate, mineral oil, propylene glycol, sodium lauryl sulfate, sorbic acid, steareth-2, steareth-100, stearyl alcohol, water, and white petrolatum
Available in sterile tubes containing 15 g, 45 g, and 60 g ointment
Packaged in tubes designed for topical dermatologic application facilitating measured dosing
Formulation optimized for medium potency topical corticosteroid effect with favorable skin absorption and tolerability
Preserved with sorbic acid to maintain formulation stability and prevent microbial contamination
Non-aqueous base facilitating prolonged skin contact and increased hydration
Manufactured by Ranbaxy Laboratories Inc., ensuring pharmaceutical grade consistency
Storage recommended between 15°C to 26°C (59°F to 78°F) to maintain stability
Formulation does not contain alcohol, minimizing drying effects on skin
Compatibility with common dermatological adjunct therapies permitted with physician oversight
Contains excipients providing emollient properties to assist in repair of dry, inflamed skin
Removal and replacement intervals not specified but recommended per clinical condition and physician guidance
No generic Westcort ointment available as the brand is discontinued in the U.S., although generic hydrocortisone valerate topical formulations may be accessible
Packaging includes product labeling with detailed application instructions and warnings